메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 6, 2025 -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The presentation, titled "Precision In Vivo CAR-T Generation via CLAMP-
- 김갑성 기자
- 2025-12-06 22:45
Seegene Establishes French Subsidiary to Expand European Footprint

- France becomes Seegene's ninth overseas sales subsidiary and third in Europe, following Italy and Germany - The country ranks as Europe's second-largest molecular diagnostics market, driven by demand in sexually transmitted infections and gastrointestinal testing, and respiratory virus detection. - The new subsidiary is expected to accelerate broader adoption of Seegene's developing solutions, CURECA™ and STAgora™, in Europe SEOUL, South Korea, Dec. 5, 2025 -- Seegene, Inc., a global leader in molecular diagnostics (MDx), announced today the establishment of a n
- 김갑성 기자
- 2025-12-05 22:00
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'

Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session SEOUL, South Korea, Dec. 5, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) a
- 김갑성 기자
- 2025-12-05 22:00
Prof. Gang Shen's Research Paper about Mandibular Advancement Repositioning Technology in the Journal of Aligner Orthodontics

SHANGHAI, Dec. 5, 2025 -- A clinical study developed by Professor Gang Shen's Orthodontic Team from Taikang Bybo Dental has been officially published in the Journal of Aligner Orthodontics (JAO). The article presents key findings on the use of Mandibular Advancement Repositioning Therapy (MART) implemented through the S8-SGTB, a clear orthodontic appliance jointly developed by Smartee Denti-Technology and Prof. Gang Shen's team. The insight of the report expands non-surgical treatment possibilities for adult patients with skeletal Class II malocclusion. Titled "Working Mec
- 김갑성 기자
- 2025-12-05 18:00
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 -- At an AbbVie-sponsored symposium at the ESMO Asia Congress 2025, experts gathered to address platinum resistance in advanced ovarian cancer with Antibody Drug Conjugates (ADCs). The discussion underscored the pressing need to rethink traditional definitions of platinum resistance and explore new strategies to treat one of the most persistent and challenging treatment obsta
- 김갑성 기자
- 2025-12-05 16:00
Post-Disaster Support | Emergency Financial Assistance for Self-Financed Cancer Drugs

HONG KONG, Dec. 5, 2025 -- The Level 5 fire at Wang Fuk House, Tai Po, on 26 November has left nearly 2,000 households homeless and plunged many families into hardship. Recovery and rebuilding after a disaster is a long journey that requires support from all sectors of society. To this end, the registered Hong Kong charity "Cancer Information.com.hk Charity Foundation" (Inland Revenue Department tax-exempt ref. no.: 91/15162), with generous funding from the Li Ka Shing Foundation, is launching an emergency drug subsidy programme specifically for cancer patients or survivors a
- 김갑성 기자
- 2025-12-05 14:03
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet

NANJING, China and GAITHERSBURG, Md., Dec. 5, 2025 -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA) on The Lancet Gastroenterology and Hepatology (Impact Factor: 38.6). Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, frequently driven by FGFR2 fusions-genomic alterations that are targetable by FGFR inhibitors such as pemigatinib and futibatinib. However, resistance to these agents commonly arises due to secondary FGFR2
- 김갑성 기자
- 2025-12-05 12:31
ALL CONEC Selected for Dream Venture Star 11, Prize Award and MOU Scheduled on November 14

SEOUL, South Korea, Dec. 5, 2025 -- ALL CONEC has been selected for the Dream Venture Star (DVS) 11 "Oracle × Uclick Program Business Meetup" support initiative. The official event will take place on November 14 at the Daejeon Center for Creative Economy and Innovation, where ALL CONEC will receive a prize as a selected company and sign an official memorandum of understanding (MOU) related to the program. ALL CONEC develops digital prosthetic production solutions—including AI CAD, ERP, a 3D viewer, and IoT 3D printers—and provides a digital workflow platform that connec
- 김갑성 기자
- 2025-12-05 11:00
Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation

[ 메디채널 김갑성 기자 ] Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian markets KUALA LUMPUR, Malaysia, Dec. 5, 2025 -- Agilent Technologies Inc. (NYSE: A) announced the expansion of their strategic collaboration with Monash University in Malaysia to establish a state-of-the-art MUMPMP-Agilent BioDiscovery Hub aimed at accelerating regional biotechnology research and innovation. The new Memorandum of Understanding (MOU) was signed as part of the celebration of their 15-year strategic partnershi
- 김갑성 기자
- 2025-12-05 09:30
OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies

SHANGHAI, Dec. 5, 2025 -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100 million Series A financing closed in June 2025. The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital. Founded in March 2025, OTR Therapeutics is establishing a novel, scalable, and capital-efficient model that synergizes internal R&D with strategic curation of high-potential external inn
- 김갑성 기자
- 2025-12-05 09:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분